These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 31160074)

  • 1. Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma.
    Nasioudis D; Kahn R; Chapman-Davis E; Frey MK; Caputo TA; Witkin SS; Holcomb K
    Gynecol Oncol; 2019 Aug; 154(2):401-404. PubMed ID: 31160074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ascites volume at the time of primary debulking and overall survival of patients with advanced epithelial ovarian cancer.
    Nasioudis D; Byrne M; Ko EM; Haggerty AF; Cory L; Giuntoli Ii RL; Kim SH; Latif NA
    Int J Gynecol Cancer; 2021 Dec; 31(12):1579-1583. PubMed ID: 34702746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in surgical complexity and treatment modalities utilized in the management of ovarian cancer in an era of neoadjuvant chemotherapy.
    Horner W; Peng K; Pleasant V; Brackmann M; Ebott J; Gutfreund R; McLean K; Reynolds RK; Uppal S
    Gynecol Oncol; 2019 Aug; 154(2):283-289. PubMed ID: 31196575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?
    Tseng JH; Cowan RA; Zhou Q; Iasonos A; Byrne M; Polcino T; Polen-De C; Gardner GJ; Sonoda Y; Zivanovic O; Abu-Rustum NR; Long Roche K; Chi DS
    Gynecol Oncol; 2018 Oct; 151(1):24-31. PubMed ID: 30126704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
    Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
    Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
    Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
    Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
    Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer.
    Greer A; Gockley A; Manning-Geist B; Melamed A; Sisodia RC; Berkowitz R; Horowitz N; Del Carmen M; Growdon WB; Worley M
    Int J Gynecol Cancer; 2021 Oct; 31(10):1341-1347. PubMed ID: 34429355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery.
    Sørensen SM; Schnack TH; Høgdall C
    Acta Obstet Gynecol Scand; 2019 Jan; 98(1):34-43. PubMed ID: 30168853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer.
    Vermeulen CKM; Tadesse W; Timmermans M; Kruitwagen RFPM; Walsh T
    Eur J Obstet Gynecol Reprod Biol; 2017 Dec; 219():100-105. PubMed ID: 29078115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of systematic lymphadenectomy at the time of interval debulking surgery for patients with advanced-stage epithelial ovarian carcinoma who achieved complete gross resection.
    Nasioudis D; Gysler S; Latif NA; Giuntoli RL; Kim SH; Ko EM
    Int J Gynecol Cancer; 2024 Jul; 34(7):969-974. PubMed ID: 38754968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
    Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
    Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive surgery in advanced stage malignant ovarian germ cell tumors.
    Karalok A; Comert GK; Kilic C; Turkmen O; Kilic F; Basaran D; Boyraz G; Tekin ÖM; Turan T
    J Gynecol Obstet Hum Reprod; 2019 Sep; 48(7):461-466. PubMed ID: 31228608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of the PlasmaJet® Device in advanced stage ovarian carcinoma: a systematic review.
    Nieuwenhuyzen-de Boer GM; van der Kooy J; van Beekhuizen HJ
    J Ovarian Res; 2019 Jul; 12(1):71. PubMed ID: 31362769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of residual disease in advanced stage malignant ovarian germ cell tumors.
    Nasioudis D; Chapman-Davis E; Frey MK; Caputo TA; Witkin SS; Holcomb K
    Int J Gynecol Cancer; 2019 Mar; 29(3):554-559. PubMed ID: 30700566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Gynecol Oncol; 2018 Aug; 150(2):233-238. PubMed ID: 29933927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of surgical volume on short-term outcomes of cytoreductive surgery for advanced-stage ovarian cancer: A population-based study from the Dutch Gynecological Oncology Audit.
    Algera MD; van Driel WJ; Slangen BFM; Wouters MWJM; Kruitwagen RFPM;
    Gynecol Oncol; 2024 Jul; 186():144-153. PubMed ID: 38688188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of celiac lymph node involvement in patients after frontline treatment for advanced ovarian cancer.
    Angeles MA; Ferron G; Cabarrou B; Balague G; Martínez-Gómez C; Gladieff L; Pomel C; Martinez A
    Eur J Surg Oncol; 2019 Aug; 45(8):1410-1416. PubMed ID: 30857876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ninety-Day Mortality as a Reporting Parameter for High-Grade Serous Ovarian Cancer Cytoreduction Surgery.
    Spencer RJ; Hacker KE; Griggs JJ; Rice LW; Reynolds RK; Uppal S
    Obstet Gynecol; 2017 Aug; 130(2):305-314. PubMed ID: 28697111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.